663 related articles for article (PubMed ID: 26946341)
1. Glycation in Parkinson's disease and Alzheimer's disease.
Vicente Miranda H; El-Agnaf OM; Outeiro TF
Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
[TBL] [Abstract][Full Text] [Related]
2. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
[TBL] [Abstract][Full Text] [Related]
3. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
5. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
6. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
Atsmon-Raz Y; Miller Y
ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
[TBL] [Abstract][Full Text] [Related]
7. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
8. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
[TBL] [Abstract][Full Text] [Related]
9. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
[TBL] [Abstract][Full Text] [Related]
10. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.
Majd S; Power JH; Grantham HJ
BMC Neurosci; 2015 Oct; 16():69. PubMed ID: 26499115
[TBL] [Abstract][Full Text] [Related]
11. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
12. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease.
Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D
Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892
[TBL] [Abstract][Full Text] [Related]
13. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease.
Vella LJ; Hill AF; Cheng L
Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304
[TBL] [Abstract][Full Text] [Related]
14. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
Choi ML; Gandhi S
FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
[TBL] [Abstract][Full Text] [Related]
15. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
Forloni G; Artuso V; La Vitola P; Balducci C
Mov Disord; 2016 Jun; 31(6):771-81. PubMed ID: 27030592
[TBL] [Abstract][Full Text] [Related]
16. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
17. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases.
Wojtunik-Kulesza K; Oniszczuk A; Waksmundzka-Hajnos M
Biomed Pharmacother; 2019 Mar; 111():1277-1289. PubMed ID: 30841441
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective.
Li J; Liu D; Sun L; Lu Y; Zhang Z
J Neurol Sci; 2012 Jun; 317(1-2):1-5. PubMed ID: 22410257
[TBL] [Abstract][Full Text] [Related]
20. Commentary to "Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease".
Mandal PK; Pettegrew JW
Neurochem Res; 2008 Jun; 33(6):1168. PubMed ID: 18049892
[No Abstract] [Full Text] [Related]
[Next] [New Search]